NuGen Medical Devices Inc. presented new data from a preliminary trial that semaglutide (ozempic) is chemically stable after it is administered through NuGen's InsuJet needle-free injection device. NuGen first announced on April 10th, 2023 it had engaged Basic Pharma Technologies in the Netherlands to preform an assessment and feasibility study, including validation testing of semaglutide if administered using NuGen's needle free injection. Laboratory results received on October 5th,2023, from Basic Pharma showed no differences were detected between the use of the Ozempic pen and the InsuJetTM needle free device.

Specifically, commercially available Ozempic was loaded into and discharged from the InsuJet device and compared to the liquid discharged from the commercially available Ozempic pen. No degradants were detected from the use of the InsuJet device via HPLC (High-Performance Liquid Chromatography) analysis of the liquid .